Nuveen LLC Acquires New Position in Lyell Immunopharma, Inc. $LYEL

Nuveen LLC purchased a new position in Lyell Immunopharma, Inc. (NASDAQ:LYEL) in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor purchased 641,173 shares of the company’s stock, valued at approximately $345,000.

Other hedge funds and other institutional investors have also added to or reduced their stakes in the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Lyell Immunopharma by 13.4% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 308,551 shares of the company’s stock worth $197,000 after acquiring an additional 36,555 shares in the last quarter. BNP Paribas Financial Markets purchased a new stake in shares of Lyell Immunopharma during the 4th quarter worth approximately $162,000. D. E. Shaw & Co. Inc. raised its holdings in shares of Lyell Immunopharma by 104.4% during the 4th quarter. D. E. Shaw & Co. Inc. now owns 966,265 shares of the company’s stock worth $618,000 after acquiring an additional 493,639 shares in the last quarter. venBio Partners LLC purchased a new stake in shares of Lyell Immunopharma during the 4th quarter worth approximately $4,545,000. Finally, Jacobs Levy Equity Management Inc. purchased a new stake in shares of Lyell Immunopharma during the 4th quarter worth approximately $887,000. 66.05% of the stock is currently owned by institutional investors.

Lyell Immunopharma Stock Up 3.7%

Shares of Lyell Immunopharma stock opened at $12.15 on Friday. The stock’s fifty day moving average is $10.67 and its two-hundred day moving average is $10.35. The company has a market capitalization of $233.40 million, a PE ratio of -0.50 and a beta of -0.19. Lyell Immunopharma, Inc. has a 52 week low of $7.65 and a 52 week high of $32.00.

Lyell Immunopharma (NASDAQ:LYEL) last posted its quarterly earnings results on Tuesday, August 12th. The company reported ($2.89) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($3.80) by $0.91. Lyell Immunopharma had a negative return on equity of 85.58% and a negative net margin of 552,328.31%.The business had revenue of $0.01 million for the quarter, compared to the consensus estimate of $0.00 million. As a group, research analysts anticipate that Lyell Immunopharma, Inc. will post -0.78 earnings per share for the current year.

Wall Street Analyst Weigh In

Several research firms recently weighed in on LYEL. Wall Street Zen upgraded Lyell Immunopharma from a “sell” rating to a “hold” rating in a report on Monday, September 1st. HC Wainwright restated a “neutral” rating and set a $10.00 price target on shares of Lyell Immunopharma in a report on Tuesday, June 24th. One investment analyst has rated the stock with a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Lyell Immunopharma has a consensus rating of “Reduce” and a consensus price target of $15.00.

Lyell Immunopharma Company Profile

Lyell Immunopharma, Inc, a clinical-stage cell therapy company, develops T cell reprogramming technologies for patients with solid tumors. The company develops therapies using an ex vivo genetic reprogramming technologies, such as c Jun overexpression and NR4A3 gene knockout, to endow resistance to T cell exhaustion; and an ex vivo epigenetic reprogramming technologies, including Epi R to generate population of T cells with durable stemness, and Stim R, a proprietary synthetic cell mimetic.